Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Exelixis (EXEL)

Exelixis Q4 revenue rises to $567 million; 2025 revenue guidance maintained

Positive Impact 3 of 5 earnings Written later

Exelixis reported fourth-quarter 2024 total revenues of $567 million, up from $480 million a year earlier, and GAAP diluted EPS of $0.48, up from $0.27. For fiscal 2024, total revenues were $2.17 billion and GAAP net income was $521.3 million, compared with $1.83 billion and $207.8 million in 2023. The company kept its 2025 financial guidance unchanged, and that guidance does not include any impact from a possible U.S. approval of CABOMETYX for neuroendocrine tumors.

Key points

  • Q4 2024 net product revenues were $515.2 million, versus $429.3 million in Q4 2023.
  • Q4 2024 non-GAAP diluted EPS was $0.55, versus $0.33 a year earlier.
  • 2025 total revenues guidance is $2.15 billion to $2.25 billion, unchanged from prior guidance.
  • The FDA's PDUFA target action date for CABOMETYX in advanced neuroendocrine tumors is April 3, 2025.

The filing

CompanyExelixis (EXEL)
Form8-K, current report
Filed with the SECFeb 11, 2025, 4:08 PM ET
Accession number0000939767-25-000017

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 11, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.